Article info
Systemic lupus erythematosus
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
- Correspondence to Professor David Klatzmann, Sorbonne Université - INSERM UMRS959, Sorbonne Universite, Paris 75006, France; david.klatzmann{at}sorbonne-universite.fr
Citation
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
Publication history
- Received March 17, 2022
- Accepted July 20, 2022
- First published August 16, 2022.
Online issue publication
November 10, 2022
Article Versions
- Previous version (16 August 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.